INIS
patients
100%
humans
100%
cancer
50%
risks
50%
biological markers
50%
mice
50%
blood
50%
signals
50%
genetics
50%
in vivo
50%
in vitro
50%
rna
50%
matrices
50%
biopsy
50%
Medicine and Dentistry
Anthracycline
100%
Cardiotoxicity
100%
Therapeutic Procedure
100%
Patient
28%
Biopsy Sample
14%
In Vitro
14%
Pathophysiology
14%
Transcriptome
14%
Biological Marker
14%
Motivation
14%
Cells
14%
Blood Sampling
14%
Malignant Neoplasm
14%
RNA Sequencing
7%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
100%
Cardiotoxicity
100%
Malignant Neoplasm
14%
Mouse Model
14%
Transcriptome
14%
Biological Marker
14%
Pathophysiology
14%
RNA
14%